The European Medicines Agency (EMEA) has been made aware of new reports of neuro-psychiatric adverse events occurring with the use of Tamiflu originating from Japan. These cases have been detected through the routine safety monitoring. www.emea.europa.eu/pdfs/general/direct/pr/13456607en.pdf - 23 Mar 2007
Printen
Doorsturen